in

uniQure, CSL Behring Collaborate on Hemophilia B Gene Therapy in Over $1.6-Billion Deal

uniQure and CSL Behring announced on June 24, 2020 that they are entering into a license agreement to provide CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQure s investigational gene therapy for patients with hemophilia B, in a deal worth potentially over $1.6 billio

Source link

4”x4 Yard Gauze Bandage Rolls Stretched Sterile First Aid Kit Medical Tape Wrap

The Expedition to Heaven on Earth